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http://dx.doi.org/10Background and Aims. Severe influenza A(H1N1)pdm2009 virus infection cases are
characterized by sustained immune activation during influenza pandemics. Seasonal flu
data suggest that immune mediators could be modified by wave-related changes. Our
aim was to determine the behavior of soluble and cell-related mediators in two waves
at the epicenter of the 2009 influenza pandemic.
Methods. Leukocyte surface activation markers were studied in serum from periph-
eral blood samples, collected from the 1st (AprileMay, 2009) and 2nd (October
2009eFebruary 2010) pandemic waves. Patients with confirmed influenza A(H1N1)
pdm2009 virus infection (H1N1), influenza-like illness (ILI) or healthy donors (H)
were analyzed.
Results. Serum IL-6, IL-4 and IL-10 levels were elevated in H1N1 patients from the 2nd
pandemic wave. Additionally, the frequency of helper and cytotoxic T cells was reduced
during the 1st wave, whereas CD69 expression in helper T cells was increased in the 2nd
wave for both H1N1 and ILI patients. In contrast, CD62L expression in granulocytes
from the ILI group was increased in both waves but in monocytes only in the 2nd wave.
Triggering Receptor Expressed on Myeloid cells (TREM)-1 expression was elevated only
in H1N1 patients at the 1st wave.
Conclusions. Our results show that during the 2009 influenza pandemic a T cell activa-
tion phenotype is observed in a wave-dependent fashion, with an expanded activation in
the 2nd wave, compared to the 1st wave. Conversely, granulocyte and monocyte activation
is infection-dependent. This evidence collected at the pandemic epicenter in 2009 couldntributed equally to this project.
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652 Arriaga-Pizano et al./ Archives of Medical Research 46 (2015) 651e658help us understand the differences in the underlying cellular mechanisms that drive the
wave-related immune profile behaviors that occur against influenza viruses during pan-
demics.  2015 IMSS. Published by Elsevier Inc.
Key Words: Immune profiles, Pandemic A(H1N1)pdm2009 influenza, Pandemic waves.Introduction Siglo XXI, IMSS, Mexico City (Research project: CNICInfluenza A(H1N1)pdm09 virus infection resulted in high
morbidity and mortality rates in young adults during the
Mexican outbreak (1,2). Some underlying conditions (3) or
simultaneous contact with infectious foci (4) were related
to influenza severity. Acute manifestations in young-
immunocompetent subjects resembled infections by highly
pathogenic pandemic influenza viruses, such as the H5N1
avian influenza and the 1918 H1N1 virus (2). The immuno-
logical profiles of previous pandemics (e.g., 1918, 1957 and
1968) showed hypercytokinemia and exacerbated leukocyte
activation (5,6), making it relevant to characterize the inflam-
matory response to the influenza A(H1N1)pdm09 virus (7).
Multiple waves during influenza pandemics have been
observed (8e10), and mathematical models show that viral
mutations (11), social interventions (12e15) and ratio of
immunocompromised individuals (16e18) determine the
potential and magnitude of subsequent waves. These theo-
retical models are essential for analyzing multiple influenza
outbreak waves and pandemic planning (19). In addition,
seasonal influenza has shown different immune behaviors
among waves (20,21). However, no evidence has been re-
ported regarding the wave-related changes for immune sol-
uble and cellular markers in the first influenza pandemic of
the 21st century.
In addition to soluble mediators, surface cellular
markers such as CD69 (an early lymphocyte activation
marker), lung homing related CD62L, Triggering Receptor
Expressed on Myeloid cells (TREM)-1 and HLA-DR have
been useful for inflammation analysis in influenza infec-
tions (22), inflammatory systemic syndrome (23) and hy-
persensitivity states (24).
Furthermore, multi-wave epidemics such as in Mexico
2009 offer opportunities to test the immune nature of short-
term shifts in humoral and cellular responses. We report
the immunological profiles (cytokine and chemokine levels,
proportion of circulating leukocytes and activation pheno-
type, based on surface expression markers) in RT-PCR veri-
fied patients for influenza A(H1N1)pdm2009 virus (H1N1),
influenza-like illness (ILI) and healthy donors (H) during two
infection waves in the epicenter of the Mexican outbreak.Materials and Methods
Patients and Sample Collection
Our study was conducted by the Medical Research Unit in
Immunochemistry (UIMIQ) and approved by the Ethics
and Research Committee of the National Medical Center2010-785-002). Mexico City patients from the 1st (Apri-
leMay 2009) and 2nd (October 2009eFebruary 2010)
pandemic waves were enrolled.
Sixty-two patients from the Specialties Hospital of the
National Medical Center Siglo XXI, IMSS or the Regional
Hospital ‘‘Dr. Carlos MacGregor’’, and 12 healthy volun-
teers were analyzed. All subjects were included after
informed consent had been read and signed according to
guidelines established by the local ethics committee. Study
groups were classified into the following: a) influenza-like
illness (ILI) patients from the 1st (n 5 10) and 2nd
(n 5 20) waves; b) confirmed influenza A(H1N1)pdm09
virus-infected (H1N1) patients from the 1st (n 5 9) and
2nd (n 5 23) waves; or c) healthy volunteers (H, n 5 12).
None of the patients from the 2nd wave was recruited in
the 1st one. ILI was defined as a combination of cough,
headache, and fever with one or more of the following
symptoms: sore throat, rhinorrhea, arthralgia, myalgia,
prostration, thoracic pain, abdominal pain, nasal conges-
tion, diarrhea and irritability, as previously described (25).
All patients were tested for influenza A(H1N1)pdm09 viral
infection using specific real-time reverse transcriptionepo-
lymerase chain reaction (rRT-PCR) according to the CDC
protocol of real-time RT-PCR for swine influenza (H1N1)
(26). The analysis was performed at the Unit for Epidemi-
ological Surveillance, National Medical Centre ‘‘La Raza’’,
IMSS, Mexico City.
All participants were clinically evaluated at the time of
their first admission in the emergency room; the following
signs or symptoms were assessed: fever ($38C), head-
ache, cough, sore throat, rhinorrhea, myalgia, joint pain,
dyspnea, conjunctivitis, sore back, diarrhea, asthenia,
nausea, and/or vomiting. Systemic Inflammatory Response
Syndrome (SIRS) was diagnosed according to the definition
of the American College of Chest Physicians/Society of
Critical Care Medicine Consensus Conference (27). None
of the patients had bacterial co-infections or previous influ-
enza vaccination. Afterwards, blood specimens from each
subject were collected in silicone and EDTA-coated tubes
(BD Vacutainer, Franklin Lakes, NJ). Serum samples were
obtained and stored at 70C and EDTA samples were pro-
cessed immediately. Due to logistic problems, in some
cases we were unable to obtain serum and blood cells from
the same subject for all immune evaluations.
Determination of Anti-Influenza Titers
The titer of anti-hemagglutinin antibodies was determined
by hemagglutination inhibition test. Serum samples were
Table 1. Epidemiological data
1st wave (n [ 19) 2nd wave (n [ 43)
H
(n [ 12)
ILI
(n [ 10)
H1N1
(n [ 9)
ILI
(n [ 20)
H1N1
(n [ 23)
Gender
Female 4 4 12 10 7
Male 6 5 8 13 5
Age (years)
Media 41 38.2 48a**/b* 30.3b* 30.8a**
Max 49 78 76 59 64
Min 15 15 18 16 22
1st wave: AprileMay 2009; 2nd wave: October 2009eFebruary 2010.
*p !0.05.
**p !0.01.
aILI or H1N1 (2nd wave) vs. H.
bILI vs. H1N1 at the same wave; Kruskal-Wallis test with Dunn’s multiple
comparison post-test.
653Immune Profiles in Pandemic Influenza Waves of 2009heated at 56C for 30 min and serially diluted in PBS-BSA,
pH 5 6.9. Fifty mL of serum dilutions were incubated for
30 min at 37oC with an equal volume of pre-diluted virus
(influenza A/Mexico/4482/2009, provided by InDRE) con-
taining 8 HA units. After incubation, titers were measured
by inverse dilution where 100% of erythrocytes aggluti-
nated. Titers of 1:40 or above were considered positive
(28,29).
Cytokine and Chemokine Quantification
Serum cytokine (IL-2, IL-4, IL-6, IL-10, TNF-a, IFN-g
and IL-17A) and chemokine (CXCL8, CXCL9, CCL2
and CXCL10) concentrations were determined using a
cytometric bead array (CBA) kit (BD PharMingen, San
Diego, CA), according to the manufacturer’s instructions.
Log-transformed data were used to construct standard
curves that were fitted to 10 discrete points using a 4-
parameter logistic model. The concentrations in the test
samples were calculated interpolating from their corre-
sponding standard curves. Data analysis was performed us-
ing the GraphPad Prism software (GraphPad Software, San
Diego, CA).
Peripheral Leukocyte Surface Marker Assessments
Whole blood samples were evaluated for: a) autofluores-
cence; b) six-color antibody-conjugated cocktail, which
included anti-CD19/FITC (Clone: HIB19, BD Bioscience),
anti-TREM-1/PE (Clone: 193015, R&D Systems), anti-
CD86/PE-Cy5 (Clone: FUN-1, BD Bioscience), anti-CD14/
PE-Cy7 (Clone: M5E2, BD Bioscience), anti-CD62L/APC
(Clone: Dreg-56, Invitrogen) and anti-HLA-DR/APC-Cy7
(Clone: M5E2, BD Bioscience); or c) five-color cocktail,
which included anti-CD3/FITC (Clone: HIT3, BD Biosci-
ence), anti-CD69/PE (Clone: HIB19, BD Bioscience),
anti-CD4/PE-Cy5 (Clone: RPA-T4, BD Bioscience), anti-
CD8/APC (Clone: 3B5, Invitrogen) and anti-CD19/PerCP
(Clone: SJ25-C1, Caltag). Appropriate isotype controls
were also used. After 15 min in the dark at room temper-
ature (RT), 500 mL of FACS Lysing Solution (Becton-
Dickinson, CA) were added, and incubated for 10 min at
RT. The cell suspensions were washed once with a 1 mL
fraction of phosphate-buffered saline by centrifugation at
900  g for 5 min at RT. Ten thousand single leukocytes
were acquired using FACSDiva 6.1.3 software in a
FACSAria I flow cytometer (BD Biosciences). Final anal-
ysis was performed using the Infinicyt Analytical Software
(Cytognos). The analysis algorithms to identify and charac-
terize leukocytes are presented in Supplementary Figure 1.
Percentages of CD69, CD62L, TREM-1 and HLA-DR pos-
itive cells were determined in: CD3þCD4þ (helper T lym-
phocytes), CD3þCD8þ (cytotoxic T lymphocytes), CD19þ
(B-lymphocytes), CD14þ (monocytes) or granulocyte-
gated cells (defined as FSChighSSChigh as routinely
analyzed in clinical hematocytometers) (30). Additionally,granulocytes were CD3CD19CD14 (31). For each
population, the relative expression of each marker was
determined by Mean Fluorescence Intensity (MFI). Repre-
sentative histograms are presented in Supplementary
Figure 2.
Statistical Analysis
To know if medians were different among groups, Kruskal-
Wallis test and Dunn’s multiple comparison post-test were
calculated; p!0.05 was considered statistically significant.
All statistical analyses and graphics were performed with
Prism 5 software (Graphpad Software, La Jolla, CA).Results
Demographic and Clinical Characteristics
Demographic and clinical characteristics of the patients for
the 1st and 2nd influenza waves are summarized in Tables 1
and 2. Based on gender distribution, no significant differ-
ences were detected among the groups. However, we found
that ILI patients were significantly older than H1N1 pa-
tients in the 2nd wave ( p !0.05). Major influenza signs
and symptoms, underlying conditions, and fatal outcomes
were similar among groups. In contrast, the SIRS rate
was higher in the 1st wave (60% for ILI and 90% for
H1N1) compared to the 2nd wave (15% for ILI and 17%
for H1N1). Both ILI and H1N1 patients from the 1st wave
were negative to anti-A(H1N1)pdm2009 antibodies,
showing titers!40; on the other hand, seven patients (five
ILI and two H1N1) in the 2nd wave were positive for anti-
A(H1N1)pdm2009 with titers O40 (Table 2).
No hypercytokinemia but differential cytokine/chemo-
kine concentrations between waves are described. Table 3
summarizes the cytokine and chemokine determinations.
No significant differences were found for IL-2, TNF-a,
Table 2. Clinical data
1st wave 2nd wave
ILI
(n [ 10)
H1N1
(n [ 9)
ILI
(n [ 20)
H1N1
(n [ 23)
Major signs and symptoms
Fever (O38 C) 10/10 8/9 20/20 23/23
Headache 8/10 9/9 19/20 21/23
Cough 8/10 9/9 20/20 23/23
Throat pain 4/10 6/9 4/20 6/23
Diarrhea 3/10 0/9 1/20 1/23
Days of evolution at
diagnosis
3.7  2.8 5.7  3.6 4.2  4.5 4.5  5.9
SIRS 6/10a* 8/9b* 3/20a* 4/23b*
Underlying conditions
Tobacco consumption 3/10 6/9 8/20 5/23
Diabetes 0/10 1/9 5/20 2/23
COPD 0/10 4/9 2/20 1/23
Dyslipidemia 1/10 2/9 3/20 1/23
Hypertension 0/10 4/9 7/20 2/23
Asthma 1/10 2/9 4/20 2/23
H1N1pdm2009
antibody titers (O40)
0/10 0/9 5/20 2/23
Fatal outcome 0/10 0/9 2/20 0/23
SIRS, systemic inflammatory response syndrome; COPD, chronic obstruc-
tive pulmonary disease; 1st wave: AprileMay 2009; 2nd wave: October
2009eFebruary 2010; aILI (1st wave) vs. ILI (2nd wave); bH1N1 (1st wave)
vs. H1N1 (2nd wave); Kruskal-Wallis test with Dunn’s multiple compari-
son post-test.
*p !0.05.
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Additionally, outlier values had no correlation with any ILI
or H1N1 group, disease severity or fatal outcome. IL-6 con-
centration in ILI and H1N1 groups was higher than in H
group for the 1st and 2nd waves ( p !0.05). In contrast,Table 3. Serum cytokine and chemokine levels
Cytokine/
Chemokine
(pg/mL)
1st wave
ILI (n [ 7) H1N1 (n [ 9)
IL-2 2.9  0.9 LOD
IL-4 6.0  3.2 5.4  4.6
IL-6 16.3  21.1 47.7  85.1
IL-10 LOD 4.9  2.5
TNF-a LOD LOD
IFN-g LOD LOD
IL-17A LOD LOD
CXCL10 (mg/mL) 2  1.2 3.6  1.4
CCL2 111.2  124.8 156.3  216.0
CXCL9 (mg/mL) 0.9  0.5 1.6  1.6
CXCL8 26.3  31a*/c* 35.8  14.87a*/d*
Limits of detection (pg/mL): 2.6 (IL-2); 4.9 (IL-4); 2.4 (IL-6); 4.5 (IL-10); 3.
(CXCL9); 0.2 (CXCL8); 1st wave: AprileMay 2009; 2nd wave: October 2009e
Kruskal-Wallis test with Dunn’s multiple comparison post-test; *p !0.05.
aILI or H1N1 (1st wave) vs. H.
bILI vs. H1N1 at the same wave.
cILI (1st wave) vs. ILI (2nd wave).
dH1N1 (1st wave) vs. H1N1 (2nd wave).CXCL8 was significantly lower in ILI and H1N1 compared
to the H group in the 1st wave ( p!0.05), and still lower in
the 2nd wave; however, they did not reach statistical signif-
icance. Finally, IL-4 concentration in the H1N1 group was
higher than in the ILI group ( p !0.05); IL-10 concentra-
tion in the H1N1 was elevated in contrast with the H group
( p!0.05), and IL-4 and IL-10 concentrations in the H1N1
group were higher in the 2nd wave compared to the 1st
wave.Leucocyte Activation Is More Evident During the 2nd
Pandemic Wave
No significant differences in the peripheral percentages of
granulocytes, monocytes or lymphocytes were observed
among groups (Supplementary Table 1). In contrast, per-
centage of helper T cells in the ILI and H1N1 groups was
significantly lower in the 1st wave than in the 2nd wave
( p!0.01); helper T cells in the ILI and H1N1groups were
also significantly lower than in the H group (Supplementary
Table 1 and Figure 1A, p!0.05 and p!0.01, respectively).
Similar results were observed for cytotoxic T cells in ILI and
H1N1 groups where the percentage was lower in the 1st
wave than in the 2nd wave (Supplementary Table 1 and
Figure 1B, p!0.01 and p!0.05).
Finally, we observed that CD69 expression on helper
T cells in the ILI and H1N1 groups was lower in the 1st
wave compared to the 2nd wave ( p !0.01 and p !0.05,
respectively); however, for the 2nd wave, CD69 expression
on helper T cells was higher in the ILI and H1N1 groups in
comparison with the H group (Figure 1C; p !0.05 and
p !0.01, respectively). We did not observe statistical dif-
ferences for the expression of CD69 in cytotoxic T cells2nd wave
H (n [ 12)ILI (n [ 18) H1N1 (n [ 23)
2.5  0.3 2.7  0.8 LOD
3.9  59.1b* 14.3  40.4b* 3.9  0.00
58.9  257.4a* 173.4  795.3a* 2.3  1.2a*
5.5  27.2 11.4  20.5a* 3.9  1.3a*
3.4  2.6 3.3  2.30 LOD
5.6  8.8 7.8  16.2 LOD
LOD 19.3  3.1 22.8  12
2.4  1.9 3.5  1.8 2.3  1.4
147.3  148 665.7  1044.3 192.1  37.2
2.5  1.9 2.9  1.8 1.2  0.9
236.4  349c* 301.7  529.5d* 580.7  766.4a*
8 (TNF-a); 3.7 (IFN-g); 18.9 (IL-17A); 2.8 (CXCL10); 2.7 (CCL2); 2.5
February 2010; LOD: lower limit of detection. Mean  SD.
Figure 1. T cell phenotype in the ILI, H1N1 and H groups from the 1st and 2nd pandemic waves. Peripheral blood leukocytes were immunostained with CD3-,
CD4-, CD8- and CD69-specific antibodies and analyzed with flow cytometry. The CD69 percentages and relative expression levels in helper (A,C) and cyto-
toxic (B,D) T cells are shown as mean and standard deviation. A Kruskal-Wallis test, which was followed by a Dunn’s multiple comparison test, was per-
formed. *p !0.05, **p !0.01.
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cytes in the ILI group was higher than in the H group at the
2nd wave (Figure 2AeB granulocytes: p !0.01; mono-
cytes: p !0.05). Unlike CD62L expression, TREM-1
expression in monocytes in the 1st wave was higher in the
H1N1 group than in the H group (Figure 2C, p !0.01).
Additionally, HLA-DR expression in monocytes in both
groups was higher in the 1st wave than in the 2nd wave,
and both waves displayed higher expression in comparison
with the H group (Figure 2D, p !0.05).Discussion
Influenza A(H1N1)pdm09 virus has shown different rates
of morbidity and mortality among different countries, sea-
sons and waves (26,32,33), reaching less mortality than
the 1918 pandemic virus (0.01e0.06 vs. 2e3%) (34).
However, the influenza A(H1N1)pdm09 virus had a higher
lethality rate in young adults compared to neonates and
elderly persons, but similar lethality in patients immuno-
compromised or affected by comorbidities during the
2009 outbreak (35). We did not find any age-associatedor clinical differences between the waves that could
explain a different immunological response against the
pandemic virus (Tables 1 and 2). Moreover, we observed
that the comorbidity and clinical diagnosis was not useful
to differentiate between the ILI and the H1N1 groups as
reported previously (36). However, we observed a lack
of antibody titersO40 in the 1st wave patients, supporting
the hypothesis for a faint immunological response against
influenza A(H1N1)pdm09 virus in the first wave. In
contrast, seven patients (five ILI and two H1N1) expressed
titersO40 during the 2nd wave, suggesting an elevated im-
mune response during the 2nd wave. Seroprevalence ana-
lysis in Mexico showed that 39% of the population was
positive after the 2nd wave, with significantly higher titers
in subjects !20 years of age (49.5%); interestingly one
third of the seropositive subjects were asymptomatic
(36). This could result from vaccination programs leading
to homologous reinfections (37), suggesting a wide spread
of wild type pandemic virus resulting in inter-pandemic
influenza exposure, thus providing short-lived protection
(38). Mathematical models have noted that early vaccina-
tion programs lead to limitation for a 2nd wave; however,
despite an early vaccination program in Mexico a 2nd
Figure 2.Monocyte and granulocyte phenotypes in the 1st and 2nd pandemic waves for the ILI, H1N1 and H groups. Peripheral blood leukocytes were immu-
nostained with CD14-, CD62L-, TREM-1- and HLA-DR-specific antibodies and analyzed with flow cytometry. The relative neutrophil CD62L (A), monocyte
CD62L (B), monocyte TREM-1 (C) and monocyte HLA-DR (D) expression levels are shown as mean and standard deviation. Kruskal-Wallis test followed by
Dunn’s multiple comparison test was performed. *p !0.05, **p !0.01.
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influenza A(H1N1)pdm09 virus.
Influenza H1N1 1918 and H5N1 avian viruses are
known for eliciting a hyper-immune response that included
high circulating cytokine and chemokine concentrations
(39). In addition, studies in patients with severe illness dur-
ing the 2006e2007 seasonal influenza, showed a high con-
centration of IL-6 (20) and IL-8 (21); in contrast, in vitro
studies showed the influenza virus as a poor inducer of
pro-inflammatory cytokines in macrophages and dendritic
cells (40). Our study reveals that IL-6 was significantly
elevated (O10-fold above controls) in both pandemic
waves (Table 3), suggesting a better infection control
because high concentrations of IL-6 have proven to confer
protective effects against influenza (41). In contrast with
other reports associating IL-6 augmentation with a poor
outcome (42) or SIRS (43), recent reports show that IL-6
is not a definitive biomarker to determine systemic inflam-
mation (42). Moreover, we observed that IL-10 concentra-
tion during the 2nd wave was higher in the H1N1 group than
in the H group. High concentrations of IL-10 could resolveinfluenza infection by promoting virus clearance and autor-
egulation (44,45). Probably in the 1st wave IL-10 was
diminished in young patients and increased in elderly
patients (46).
T cell lymphopenia was associated with influenza
A(H1N1)pdm09 infections (47,48), probably as a result of
differential lymphocyte migration into the lungs (49,50).
We observed T cell lymphopenia in patients from the 1st
but not the 2nd wave. Helper T cells showed an increase
in early activation markers such as CD69 only during the
2nd wave (Figure 1). This could be related to differential
migration patterns to lymph nodes and lungs from naive
and, predominantly, memory T lymphocytes (51,52). The
higher proportion of circulating CD69þ CD4 T cells during
the 2nd, but not the 1st wave, could be explained by memory
induced by group immunizations.
Neutrophils, the major component of granulocytes,
could contribute to lung damage; however, reduced
numbers or impaired function of these cells may lead to se-
vere influenza disease (53) with a high mortality rate
(54,55). Because granulocytes could enter the lungs by
657Immune Profiles in Pandemic Influenza Waves of 2009using CD62L (56), we tested its expression in peripheral
blood. An augmented CD62L expression in granulocytes
was observed for both waves in all patients compared with
the H group. Although CD62L is diminished during some
infections and influenza virus in vitro induces CD62L shed-
ding on neutrophils (57), it has also been reported that
CD62L is upregulated in circulating leukocytes early after
injury (58). Accordingly, CD62L is overexpressed in hu-
man proinflammatory neutrophils exposed to IFN-g
(59,60), which is elevated during acute stages of illness in
influenza infection (61). In addition, expression of
TREM-1 and HLA-DR was also evaluated in monocytes.
Interestingly, we observed increased levels in TREM-1 only
during the 1st wave, suggesting a wave-dependent differen-
tial migration in H1N1 patients; therefore, we propose that
the expression of both CD62L and TREM-1 could be useful
in the study of waves in influenza infection.
Considering all statistical differences observed in the ILI
and H1N1 groups compared with the H group, our results
showed greater immunological activity in the 2nd wave
compared with the 1st wave of influenza during the 2009
outbreak; accordingly the mortality rates were greater dur-
ing the 2nd wave (62). Our study suggests that some differ-
ential leukocyte phenotypes such as CD69 for helper
T cells, and CD62L, TREM-1 and HLA-DR for myeloid
cells could explain this epidemiological observation. Our
study has some limitations associated with: a) a relatively
small number of observations and sizeable SD for most pa-
rameters; b) serial samples were not collected; therefore, a
peak time point could have been missed; and c) signs and
symptoms from patients were not stratified, just registered
as present or absent.
In conclusion, to our knowledge this is the first report
that describes differences in the immune response during
pandemic periods, with prominent activation during the
2nd pandemic wave, which was more likely explained
by the immune response than by underlying diseases or
age. Further investigation is needed to fully understand
the underlying mechanisms driving the wave-like
behavior of immune responses against pandemic influenza
virus so that more focused therapeutic strategies can be
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